 | |
| Clinical data | |
|---|---|
| Other names | GABA-Aa5 PAM; GABA-Aα5 PAM; RG-7816; RG7816; RO-7017773; RO7017773 |
| Routes of administration | Oral[1] |
| Drug class | α5 subunit-containingGABAA receptorpositive allosteric modulator |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H23N5O4 |
| Molar mass | 409.446 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Alogabat (INNTooltip International Nonproprietary Name,USANTooltip United States Adopted Name; developmental code namesRG-7816 andRO7017773) is anα5 subunit-containingGABAA receptorpositive allosteric modulator which is under development for the treatment ofpervasive developmental disorders (e.g.,autism) andAngelman syndrome.[1][2][3][4] It is takenby mouth.[1]
As of June 2024, alogabat is inphase 2clinical trials for pervasive developmental disorders and Angelman syndrome.[1][2] It is under development byRoche.[1][2]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |